Minoryx Therapeutics/Neuraxpharm Group, Apellis Pharmaceuticals and PTC Therapeutics have all faced setbacks this week following the latest meeting of the European Medicines Agency’s human medicines committee, the CHMP.
The CHMP gave negative opinions to Minoryx /Neurapharm’s orphan drug Nezglyal (leriglitazone) and Apellis’ Syfovre (pegcetacoplan), and upheld a previous decision not to renew
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?